CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05162768
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:01.107307+00:00
Published At: 2025-10-24T00:00:00+00:00
Record Updated At: 2025-10-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Mitochondrial Myopathies", "Mitochondrial Pathology", "Mitochondrial DNA Mutation", "Mitochondrial Diseases", "Mitochondrial DNA Deletion", "Mitochondrial DNA Depletion", "Mitochondrial Metabolism Defect", "Mitochondrial Complex I Deficiency"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-24"
protocolSection.identificationModule.nctId: "NCT05162768"
protocolSection.identificationModule.officialTitle: "A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.